ロスマピモドの新興薬剤に関する洞察と市場予測：2032年

ロスマピモド（Losmapimod）は治験中の選択的p38α/Bマイトジェン活性化プロテインキナーゼ（MAPK）阻害剤です。フルクラムは、社内のプロダクトエンジンを活用し、FSHD（顔面肩甲上腕型筋ジストロフィ）患者由来の筋肉細胞においてp38α/Bの阻害がDUX4遺伝子の発現を低下させることを発見しました。

当レポートでは、主要7ヶ国におけるロスマピモド市場について調査し、市場の概要とともに、2025年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 FSHDに対するロスマピモドの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ロスマピモド市場評価

• FSHDに対するロスマピモドの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるFSHDに対するロスマピモドの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Losmapimod, Clinical Trial Description, 2023
• Table 2: Losmapimod, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Losmapimod Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Losmapimod Market Size in the US, in USD million (2019-2032)
• Table 7: Losmapimod Market Size in Germany, in USD million (2019-2032)
• Table 8: Losmapimod Market Size in France, in USD million (2019-2032)
• Table 9: Losmapimod Market Size in Italy, in USD million (2019-2032)
• Table 10: Losmapimod Market Size in Spain, in USD million (2019-2032)
• Table 11: Losmapimod Market Size in the UK, in USD million (2019-2032)
• Table 12: Losmapimod Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Losmapimod Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Losmapimod Market Size in the United States, USD million (2019-2032)
• Figure 3: Losmapimod Market Size in Germany, USD million (2019-2032)
• Figure 4: Losmapimod Market Size in France, USD million (2019-2032)
• Figure 5: Losmapimod Market Size in Italy, USD million (2019-2032)
• Figure 6: Losmapimod Market Size in Spain, USD million (2019-2032)
• Figure 7: Losmapimod Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Losmapimod Market Size in Japan, USD million (2019-2032)

“"Losmapimod Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD) in the seven major markets. A detailed picture of the losmapimod for FSHD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the losmapimod for FSHD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the losmapimod market forecast analysis for FSHD in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in FSHD.

Drug Summary:

Losmapimod is an investigational, selective p38α/B mitogen-activated protein kinase (MAPK) inhibitor. Utilizing its internal product engine, Fulcrum discovered that inhibition of p38α/B reduced expression of the DUX4 gene in muscle cells derived from patients with FSHD.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the losmapimod description, mechanism of action, dosage and administration, research and development activities in Facioscapulohumeral Muscular Dystrophy (FSHD).
• Elaborated details on losmapimod regulatory milestones and other development activities have been provided in this report.
• The report also highlights the losmapimod research and development activities in FSHD across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around losmapimod.
• The report contains forecasted sales of losmapimod for FSHD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for FSHD.
• The report also features the SWOT analysis with analyst views for losmapimod in FSHD.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Losmapimod Analytical Perspective by DelveInsight

• In-depth Losmapimod Market Assessment

This report provides a detailed market assessment of losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• Losmapimod Clinical Assessment

The report provides the clinical trials information of losmapimod for FSHD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Facioscapulohumeral Muscular Dystrophy (FSHD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence losmapimod dominance.
• Other emerging products for FSHD are expected to give tough market competition to losmapimod and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of losmapimod in FSHD.
• Our in-depth analysis of the forecasted sales data of losmapimod from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the losmapimod in FSHD.

Key Questions

• What is the product type, route of administration and mechanism of action of losmapimod?
• What is the clinical trial status of the study related to losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the losmapimod development?
• What are the key designations that have been granted to losmapimod for FSHD?
• What is the forecasted market scenario of losmapimod for FSHD?
• What are the forecasted sales of losmapimod in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to losmapimod for FSHD?
• Which are the late-stage emerging therapies under development for the treatment of FSHD?

Table of Contents

1. Report Introduction

2. Losmapimod Overview in FSHD

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Losmapimod Market Assessment

• 5.1. Market Outlook of Losmapimod in FSHD
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Losmapimod in the 7MM for FSHD
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Losmapimod in the United States for FSHD
  • 5.3.2. Market Size of Losmapimod in Germany for FSHD
  • 5.3.3. Market Size of Losmapimod in France for FSHD
  • 5.3.4. Market Size of Losmapimod in Italy for FSHD
  • 5.3.5. Market Size of Losmapimod in Spain for FSHD
  • 5.3.6. Market Size of Losmapimod in the United Kingdom for FSHD
  • 5.3.7. Market Size of Losmapimod in Japan for FSHD

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options